Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 02, 2015 9:06 PM ET


Company Overview of Stellar Biotechnologies, Inc.

Company Overview

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating protein used for generation of antibody and cell-mediated immune responses against disease indications, such as cancer, immune disorders, Alzheimer’s, and inflammatory diseases, as well as used for therapeutic vaccine conjugation in immunotherapies. The company also offers in vitro diagnostic kits for preclinical use. It provides its products under the Stellar KLH brand name. The company serves multinational biotechnology and pha...

332 East Scott Street

Port Hueneme, CA 93041

United States

23 Employees





Key Executives for Stellar Biotechnologies, Inc.

Chairman, Chief Executive Officer and President
Age: 64
Total Annual Compensation: $402.3K
Chief Financial Officer and Corporate Secretary
Age: 57
Total Annual Compensation: $175.0K
Chief Operating Officer
Age: 41
Total Annual Compensation: $178.3K
Compensation as of Fiscal Year 2014.

Stellar Biotechnologies, Inc. Key Developments

Stellar Biotechnologies Signs Collaboration Agreement with Ostiones Guerrero SA de CV to Expand KLH Aquaculture Operations

Stellar Biotechnologies, Inc. announced that the company has entered into a collaboration agreement with Ostiones Guerrero SA de CV to secure a unique strategic site in Baja California, Mexico for the development of an additional aquaculture locale and expansion of Stellar KLHTM production to meet the increasing needs of its customers. Stellar provides clinical-stage biotechnology companies with KLH, an immune-stimulating protein that is an essential ingredient in a number of human immunotherapies in various stages of clinical development. KLH can only be obtained from a scarce marine mollusk, the Giant Keyhole Limpet, which is native to a limited stretch of Pacific Ocean coastline. Under the terms of the Agreement, Stellar and Ostiones will collaborate on the design, expansion and development of marine aquaculture resources and KLH production facilities in Baja California, Mexico to provide, exclusively for Stellar, an additional site for hatchery and maturation of keyhole limpets and production of KLH. The venture will provide Ostiones with access to advanced aquaculture techniques, proprietary expertise, support services and training that will form the basis for expanding its seafood production business. Additionally, the companies are joining forces to share their vision of protecting the natural resources of the Pacific Ocean. Stellar has developed a proprietary process for KLH harvesting that does not harm the Giant Keyhole Limpets. Similarly, Ostiones is committed to sustaining ocean wildlife populations. The companies are committed to marine ecosystem sustainability as a commercial priority.

Stellar Biotechnologies, Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 02:00 PM

Stellar Biotechnologies, Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 02:00 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States.

Stellar Biotechnologies, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2015

Stellar Biotechnologies, Inc. reported consolidated earnings results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported total revenues of $187,627 compared to $114,371 for the same period a year ago. Net loss was $426,164 or $0.01 per basic and diluted share compared to $1,433,854 or $0.02 per basic and diluted share for the same period a year ago. For the year, the company reported total revenues of $400,288 compared to $173,196 for the same period a year ago. Net loss was $1,769,641 or $0.02 per basic and diluted share compared to $7,011,044 or $0.09 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $2,581,458 compared to $2,560,177 for the same period a year ago. The decrease in net loss reported in the quarter and six months ended March 31, 2015 compared to the same periods in 2014 was primarily due to significant noncash gains in the fair value of warrant liability, increased revenues and decreased research and development expenses, net of increased general and administrative expenses and increased noncash foreign exchange loss.

Similar Private Companies By Industry

Company Name Region
Nomadic Systems, Inc. United States
Hapten Sciences Development, LLC United States
New Horizons Diagnostic Corp. United States
Biotic Laboratories, Inc. United States
Aelan Cell Technologies, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Stellar Biotechnologies, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at